<div id="readability-page-1"><p>WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) Director Heidi Wagner sold 14,000 shares of the business's stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.50, for a total value of $189,000.00. Following the completion of the transaction, the director directly owned 44,930 shares in the company, valued at approximately $606,555. The trade was a 23.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.</p><div><p><span></span><span>Get <strong>WAVE Life Sciences</strong> alerts:</span></p></div><h2>WAVE Life Sciences Stock Down 5.1%</h2><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Shares of NASDAQ WVE traded down $1.08 during mid-day trading on Wednesday, hitting $20.23. 17,639,147 shares of the company were exchanged, compared to its average volume of 11,192,010. The stock has a 50 day simple moving average of $8.27 and a 200-day simple moving average of $7.90. WAVE Life Sciences Ltd. has a 1-year low of $5.28 and a 1-year high of $21.73. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of -26.97 and a beta of -1.72. </p><p>WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The firm had revenue of $7.61 million during the quarter, compared to analyst estimates of $9.85 million. WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%.  Analysts anticipate that  WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>Wave Life Sciences Rockets 70% on Historic RNA Editing Success</li></ul><p>A number of research analysts recently weighed in on WVE shares. Royal Bank Of Canada raised WAVE Life Sciences from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and upped their price objective for the stock from $9.00 to $27.00 in a report on Monday. B. Riley  reaffirmed a &#34;buy&#34; rating on shares of WAVE Life Sciences in a research note on Thursday, September 4th. Canaccord Genuity Group raised their price target on shares of WAVE Life Sciences from $19.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday. Wells Fargo &amp; Company lifted their target price on shares of WAVE Life Sciences from $16.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday. Finally, Morgan Stanley  set a $28.00 price target on WAVE Life Sciences in a research note on Monday. Twelve investment analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $27.46.</p><p><b>Get Our Latest Analysis on WVE</b></p><h2>Institutional Inflows and Outflows</h2><ul><li>Sarepta Therapeutics Inc.: Why it's a rising gene therapy star</li></ul><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its position in  WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after acquiring an additional 2,500,000 shares during the period.  683 Capital Management LLC lifted its stake in shares of  WAVE Life Sciences by 4.5% in the 2nd quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company's stock valued at $26,650,000 after purchasing an additional 175,000 shares in the last quarter.  Federated Hermes Inc. lifted its stake in shares of  WAVE Life Sciences by 678,144.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company's stock valued at $27,455,000 after purchasing an additional 3,750,140 shares in the last quarter.  Loomis Sayles &amp; Co. L P grew its holdings in shares of  WAVE Life Sciences by 35.3% during the 2nd quarter. Loomis Sayles &amp; Co. L P now owns 3,295,700 shares of the company's stock worth $21,422,000 after purchasing an additional 859,160 shares during the period.  Finally, Emerald Advisers LLC increased its position in  WAVE Life Sciences by 3.9% during the 2nd quarter. Emerald Advisers LLC now owns 3,257,119 shares of the company's stock worth $21,171,000 after purchasing an additional 123,561 shares in the last quarter. Institutional investors and hedge funds own  89.73% of the company's stock. </p><h2>WAVE Life Sciences Company Profile</h2> (Get Free Report)<p>Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than WAVE Life Sciences</li><li>Using the MarketBeat Stock Split Calculator</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>What to Know About Investing in Penny Stocks</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in WAVE Life Sciences Right Now?</h2><p>Before you consider WAVE Life Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.</p><p>While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>WAVE Life Sciences Director Heidi Wagner sold 14,000 shares at $13.50 each, totaling $189,000. This sale reduced her position by 23.76%, leaving her with 44,930 shares valued at $606,555. The transaction was disclosed in an SEC filing. WAVE Life Sciences' stock has fluctuated, with a recent price of $20.23 and a market cap of $3.38 billion. Analysts have given the stock a "Moderate Buy" rating with a consensus price target of $27.46.</p>

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells 14,000 Shares of Stock